Skip to main content
Clinical Trials/EUCTR2017-003180-35-GB
EUCTR2017-003180-35-GB
Active, not recruiting
Phase 1

Feasibility study on the effects of postnatal enalapril on maternal cardiovascular function following preterm pre-eclampsia - PICk-UP

Manchester University NHS Foundation Trust0 sites80 target enrollmentApril 30, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Manchester University NHS Foundation Trust
Enrollment
80
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 30, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Diagnosis of preterm pre\-eclampsia (pPE) in this pregnancy requiring delivery \<37 weeks gestation: new or worsening hypertension \>20 weeks with proteinuria or other features suggestive of PE (abnormal haematological, biochemical parameters, fetal growth restriction and/or low PlGF)
  • Biochemical / haematological cut\-offs:
  • \- Platelet count \<100 x109/L
  • \- Alanine amino transferase \> 50units/L
  • \- Creatinine \>90mmol/L
  • \- Abdominal circumference (AC) / estimated fetal weight (EFW) \<3rd centile
  • \- Or 2 of the following:
  • \- AC/EFW \<10th centile
  • \- AC/EFW crossing centiles by \>2 quartiles
  • \- Cerebroplacental ratio \<5th centile

Exclusion Criteria

  • Inability to consent
  • Known cardiac disease
  • Contraindication to ACE inhibitors
  • Current ACE inhibitor / ARB use
  • Renal artery stenosis

Outcomes

Primary Outcomes

Not specified

Similar Trials